PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Hum Mutat. Author manuscript; available in PMC Apr 7, 2013.
Published in final edited form as:
PMCID: PMC3618980
NIHMSID: NIHMS440758
Haploinsufficiency of SOX5 at 12p12.1 is associated with developmental delays with prominent language delay, behavior problems, and mild dysmorphic features
Allen N. Lamb,1* Jill A. Rosenfeld,1 Nicholas J. Neill,1 Michael E. Talkowski,2,3,4 Ian Blumenthal,2 Santhosh Girirajan,5 Debra Keelean-Fuller,6 Zheng Fan,6 Jill Pouncey,7 Cathy Stevens,7 Loren Mackay-Loder,8 Deborah Terespolsky,8 Patricia Bader,9 Kenneth Rosenbaum,10 Stephanie Vallee,11 John B. Moeschler,11 Roger Ladda,12 Susan Sell,12 Judith Martin,13 Shawnia Ryan,13 Marilyn C. Jones,14 Rocio Moran,15 Amy Shealy,15 Suneeta Madan-Khetarpal,16 Juliann McConnell,16 Urvashi Surti,17 Andrée Delahaye,18,19,20 Bénédicte Heron-Longe,21 Eva Pipiras,18,19,20 Brigitte Benzacken,18,19,20,22 Sandrine Passemard,20,22,23,24 Alain Verloes,20,22,23 Bertrand Isidor,25 Cedric Le Caignec,25 Gwen M. Glew,26 Kent E. Opheim,26 Evan E. Eichler,5 Cynthia C. Morton,4,27 James F. Gusella,2,3,4 Roger A. Schultz,1 Blake C. Ballif,1 and Lisa G. Shaffer1
1Signature Genomic Laboratories, PerkinElmer, Inc., Spokane, WA
2Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA
3Departments of Neurology and Genetics, Harvard Medical School, Boston, MA
4Program in Medical and Population Genetics, Broad Institute, Cambridge, MA
5University of Washington, Seattle, WA
6University of North Carolina, Chapel Hill, NC
7TC Thompson Children’s Hospital, Chattanooga, TN
8Credit Valley Hospital, Mississauga, ON
9Parkview Hospital, Fort Wayne, IN
10Children’s National Medical Center, Washington, DC
11Dartmouth-Hitchcock Medical Center, Lebanon, NH
12Penn State Milton S. Hershey Medical Center, Hershey, PA
13Providence Genetics Clinic, Spokane, WA
14Rady Children’s Hospital, University of California, San Diego, CA
15Cleveland Clinic, Cleveland, OH
16Children’s Hospital of Pittsburgh, Pittsburgh, PA
17Magee-Womens Hospital of UPMC, Pittsburgh, PA
18AP-HP, Hôpital Jean Verdier, Service d’Histologie, Embryologie, et Cytogénétique, Bondy, France
19Université Paris-Nord, Paris 13, UFR SMBH, Bobigny, France
20Inserm, U676, Paris, France
21AP-HP, Hôpital Jean Verdier, Consultations de Neuropédiatrie, Service de Pédiatrie, Bondy, France
22AP-HP, Hôpital Robert Debré, Département de Génétique, Paris, France
23Université Paris 7, Univ Paris Diderot, Sorbonne Paris Cité, Paris, France
24AP-HP, Hôpital Robert Debré, Service de Neurologie Pédiatrique, Paris, France
25CHU Nantes, Service de Génétique Medicale, Nantes, France
26Seattle Children’s Hospital, Seattle, WA
27Departments of Obstetrics, Gynecology and Reproductive Biology, and Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
For correspondence and reprints: Lisa G. Shaffer, Ph.D. Signature Genomic Laboratories, 2820 N. Astor St. Spokane, WA 99207, Ph: 509.944.4219, Fax: 509.944.4297, lisa.shaffer/at/perkinelmer.com
*Current affiliation: ARUP Laboratories, University of Utah, Salt Lake City, UT
SOX5 encodes a transcription factor involved in the regulation of chondrogenesis and the development of the nervous system. Despite its important developmental roles, SOX5 disruption has yet to be associated with human disease. We report one individual with a reciprocal translocation breakpoint within SOX5, eight individuals with intragenic SOX5 deletions (four are apparently de novo and one inherited from an affected parent), and seven individuals with larger 12p12 deletions encompassing SOX5. Common features in these subjects include prominent speech delay, intellectual disability, behavior abnormalities, and dysmorphic features. The phenotypic impact of the deletions may depend on the location of the deletion and consequently which of the three major SOX5 protein isoforms are affected. One intragenic deletion involving only untranslated exons was present in a more mildly affected subject, was inherited from a healthy parent and grandparent, and is similar to a deletion found in a control cohort. Therefore, some intragenic SOX5 deletions may have minimal phenotypic effect. Based on the location of the deletions in the subjects compared to the controls, the de novo nature of most of these deletions, and the phenotypic similarities among cases, SOX5 appears to be a dosage-sensitive, developmentally important gene.
Keywords: SOX5, developmental delay, intragenic deletion, behavior problems, microarray
Molecular cytogenetic techniques, such as array comparative genomic hybridization (aCGH), have precipitated a change in diagnostic emphasis from phenotype to genotype. Traditionally, identification of genetic causes of a syndrome first required ascertainment of multiple patients with similar phenotypes followed by a search for the underlying genetic cause. In contrast, techniques such as aCGH allow for identification of patients with similar genotypes followed by characterization of the associated phenotype. This genotype-first approach (Shaffer et al., 2007) is the only way to appreciate how similar genetic changes can lead to a phenotypic spectrum that may include nonspecific features, be variably expressed, and have overlapping features that may be found in other syndromes.
To increase the likelihood of identifying previously uncharacterized copy-number imbalances that may be causing a phenotypic spectrum of nonspecific neurodevelopmental features, we constructed whole-genome microarrays with enhanced coverage of over 500 functionally significant genes including transcription factors and other developmentally important genes. This has facilitated identification of intragenic, disease-causing deletions (Rosenfeld et al., 2009a; Rosenfeld et al., 2009b; Talkowski et al., 2011b). Another of the targeted genes, located on 12p12.1, SOX5 (SRY-box 5; OMIM 604975), has had multiple, small, apparently de novo deletions identified in patients referred for clinical aCGH testing.
SOX5, along with SOX6 and SOX13, encode members of the SOXD family of transcription factors. SOXD proteins play a role in multiple developmental pathways, including cartilage formation (Aza-Carmona et al., 2011; Lefebvre et al., 1998) and nervous system development (Kwan et al., 2008; Lai et al., 2008; Lefebvre, 2010). There are three major SOX5 transcription products, two long forms (NM_006940.4 and NM_152989.2) that code for proteins similar in size to those coded for by SOX6 and SOX13 (NP_008871.3 and NP_694534.1, respectively) and a unique short form (NM_178010.1, encoding NP_821078.1; Figure 1) (Kiselak et al., 2010). In humans, the long forms are highly expressed in chondrocytes and striated muscles (Ikeda et al., 2002) and have been seen in the fetal brain (Wunderle et al., 1996), while the short form is expressed mainly in the testes (Wunderle et al., 1996). Mouse studies have shown the long and short forms to be expressed in the brain (Kiselak et al., 2010). Mouse models support a role for long Sox5 and Sox6 in chondrogenesis (Smits et al., 2001) and in the development of neocortical projection neurons (Kwan et al., 2008; Lai et al., 2008). Homozygous loss of long Sox5 (through deletion of a coding exon specific to the long transcripts) leads to respiratory distress causing death at birth, apparently due to cleft palate and a small thoracic cage. Complete knockout of Sox6 is frequently lethal at birth; a short sternum is the only apparent skeletal defect observed, although severe dwarfism develops postnatally. Inactivation of both genes is lethal 3 days before birth, with restricted skeletal growth and ossification (Dy et al., 2008; Smits et al., 2001). The short Sox5 protein also functions as a transcription factor that drives testis-specific gene expression (Blaise et al., 1999; Budde et al., 2002; Kiselak et al., 2010; Xu et al., 2009) and likely plays a major role in the formation and function of motile cilia in brain, lung, testis, and sperm (Kiselak et al., 2010).
Figure 1
Figure 1
SOX5 transcripts, genomic environment, protein structure, and partial SOX5 deletions in this cohort
Each of the long transcripts is associated with a separate promoter region and transcription start site (TSS), supported by the presence of H3K4Me3 histone modifications, a mark commonly associated with the promoter regions of actively transcribed genes (Bernstein, 2002; Ng et al., 2003; Pokholok et al., 2005; Santos-Rosa et al., 2002; Schneider et al., 2004; Schubeler et al., 2004) (Figure 1). The two long isoforms have slightly different translation start sites, resulting in the inclusion of 13 additional amino acids at the N-terminus of NP_008871.3 (the protein product encoded by NM_006940.4; Figure 1C). The short transcript includes only 7 exons from the 3′ end of the gene, encoding a smaller protein containing the high mobility group (HMG) domain, which is involved in DNA binding and some interaction with other proteins (Aza-Carmona et al., 2011), and only one of the two coiled-coil domains found in the larger protein, which allow for homo-and heterodimerization necessary for the dimer to bind to some paired DNA binding sites (Figure 1). The TSS for the short transcript does not have a consensus H3KMe3 mark (Birney et al., 2007), which may be due to its more restricted expression (Kiselak et al., 2010).
The role of SoxD genes in many developmental pathways is well established in mouse and suggests that alterations of SOXD genes in humans could impact human disease (Lefebvre, 2010); however, no genetic studies to date have established such a link. Therefore, to understand how SOX5 alterations may contribute to disease, we analyzed the chromosomal abnormalities and phenotypes in a series of 16 subjects with structural variations disrupting SOX5, including an individual with autism that we previously reported with a small, apparently de novo, intragenic SOX5 deletion (Rosenfeld et al., 2010).
Subject ascertainment
Subjects were identified after referral for clinical molecular cytogenetic testing, either to Signature Genomic Laboratories, Seattle Children’s Hospital, Pittsburgh Cytogenetic Laboratories, Nantes University Hospital, or Hôpital Jean Verdier, or through enrollment in the Developmental Genome Anatomy Project (DGAP). Informed consent was obtained to publish the subject photographs shown here, according to protocols approved by IRB-Spokane.
Molecular cytogenetics
Oligonucleotide-based aCGH was performed on subjects 2, 3, 6, 11, 14, and subject 6’s mother using a 105K-feature whole-genome microarray [SignatureChip Oligo Solution (OS) version 1, custom-designed by Signature Genomics; manufactured by Agilent Technologies, Santa Clara, CA] as previously described (Ballif et al., 2008). Oligonucleotide-based aCGH was performed on subjects 1, 8, 9, 10, 12, 13, and subject 9’s father using a 135K-feature whole-genome microarray (SignatureChipOS version 2, custom-designed by Signature Genomics; manufactured by Roche NimbleGen, Madison, WI) as previously described (Duker et al., 2010). DNA from subject 4 was analyzed using Illumina HumanHap 300 single nucleotide polymorphism (SNP) microarray (Illumina, San Diego, CA); DNA from subject 7 was analyzed using an Agilent oligonucleotide-based 105K whole-genome microarray (SignatureSelect OS version 1.0); DNA from subject 15 was analyzed using an Agilent oligonucleotide-based 180K-feature whole-genome microarray; DNA from subject 16 was analyzed using a RocheNimbleGen oligonucleotide-based 135K-feature whole-genome CGX microarray, all according to manufacturers’ instructions.
Fluorescence in situ hybridization (FISH)
Metaphase FISH analysis was performed using a BAC clone from the abnormal region as determined by aCGH to visualize the abnormalities as previously described (Traylor et al., 2009). When available, parental samples were also assayed for the abnormal region detected by aCGH in the proband, using FISH.
Characterization of translocation breakpoint through next-generation sequencing of customized large insert libraries
Subject 5 (DGAP189) was sequenced using a custom large-insert jumping library for Illumina sequencing as previously described (Talkowski et al., 2011a). In brief, 20 μg of genomic DNA from subject 5 was sheared to ~3.5-kb fragments that were size-selected, end-repaired, and ligated to cap adaptors containing an EcoP15I restriction site and a GT overhang. Fragments were circularized with an oligonucleotide containing an AC overhang, a subject-specific bar code, and a single biotinylated thymine at the circularization junction. Circularized fragments were restriction-digested, and fragments containing the biotinylated base were captured onto streptaviden beads, purified, and Illumina paired-end adaptors were ligated. The sample was run on a single lane of a HiSeq 2000 (Illumina), using paired-end 25-bp sequencing. Reads were aligned with Burrows-Wheeler Alignment Tool (Li and Durbin, 2009) then processed with SAMtools (Li et al., 2009) and BamStat , a customized program designed to isolate anomalous read pairs indicating a chromosomal rearrangement (Talkowski et al., 2011a).
Analysis of recurrent 12p12.3p11.23 deletions
The proximal and distal breakpoint interval sequences were compared using BLAST sequence similarity (Altschul et al., 1990), and all sequence alignments were manually visualized for stretches of high sequence identity. Analysis for repeats within these breakpoint intervals were then performed using RepeatMasker (http://www.repeatmasker.org).
Molecular information
We identified eight subjects with heterozygous deletions that only involved SOX5 and ranged in size from 72 kb to 466 kb. Most deletions involved at least some of the coding exons and/or a region likely to be involved in transcription initiation, while subject 9’s deletion only involved two of the 5′ untranslated exons. Additionally, in subject 5 (DGAP189), with an apparently balanced de novo translocation [46,XX,t(11;12)(p13;p12.1)dn], we identified a translocation breakpoint within SOX5; sequencing revealed a 9-bp deletion at the breakpoint in intron 11 (chr12:23,602,450–23,602,458) and a 16-bp deletion at the breakpoint in 11p13 (chr11:35,033,903–35,033,918). No genes were present within 50 kb on either side of the 11p13 breakpoint. Depending on the abnormality size and location, the translocation or deletions are predicted to impact different protein isoforms to varying degrees (Figure 1, Tables 1 and and2).2). However, it is not always known which protein isoforms will be altered by the deletions. The deletions in subjects 7 and 8 remove the transcription initiation site of NM_006940.4, so while this likely prevents expression of that isoform, it is not known whether the other long transcript is affected. The deletion of two untranslated exons in subject 9 would alter the 5′ untranslated region of NM_152989.2, though it is uncertain if this ultimately affects gene expression or protein translation.
Table 1
Table 1
Partial SOX5 deletions in this cohort
Table 2
Table 2
Clinical information for subjects 1–9 with alterations limited to SOX5.
We identified seven additional subjects with 12p deletions encompassing multiple genes including SOX5, ranging from 1.4 Mb to 12.1 Mb and including 8 to 63 genes (Figure 2, Table 3). Two of these deletions have breakpoints within SOX5, one (in subject 15) between coding exons 3 and 4 of NM_006940.4 and extending 5′ and the other (in subject 16) between untranslated exons 3 and 4 of NM_152989.2 and extending 5′ (Figure 1). Therefore, while subject 15’s deletion is predicted to impact both long isoforms of the gene, subject 16’s deletion may only impact NM_152989.2. However, it should be noted for both of these deletions that it is not known what effect, if any, deletion of the promoter region 5′ of the untranslated exons has on expression of the shorter transcripts (Table 1).
Figure 2
Figure 2
Schematic of deletions in this cohort and molecularly defined deletions in the literature
Table 3
Table 3
Clinical information for subjects 10–16 with larger deletions including SOX5.
No other clinically significant gains or losses of DNA were identified in any of the 16 subjects.
Two subjects (12 and 13) had apparently identical 12p12.3p11.23 deletions. Query of Signature’s database of abnormalities revealed two additional cases carrying this apparently identical deletion, one referred for developmental delay (DD) and microcephaly and the other referred for pituitary dwarfism, lack of coordination, pervasive developmental delay (PDD), attention deficit-hyperactivity disorder (ADHD), and optic nerve abnormality. No additional follow-up clinical information was available. The similarity in the breakpoints of these alterations suggests that underlying genomic architecture may play a role in mediating these recurrent deletions. The aCGH results refined the intervals containing the distal and proximal breakpoints to approximately 49 kb (chr12:17,755,660–17,785,732) and 30 kb (chr12:26,583,349–26,632,432), respectively. A search for repeats within these breakpoint intervals using RepeatMasker in the reference sequence (Build 36, hg18) showed enrichment for long and short interspersed repeats (Supp. Figure S1). Specifically, L1MA4 repetitive elements with high sequence identity are present within the breakpoint intervals (Supp. Figure S2), which may be mediating recurrent deletions via non-allelic homologous recombination (NAHR), as has been proposed for long stretches of highly homologous sequences such as LINEs and Alus (Deininger and Batzer, 1999; Han et al., 2008; Shaw and Lupski, 2004).
FISH using BAC probes to the deleted region confirmed the deletion in all subjects, including diminished signals for the smallest deletions in which the BAC probes used in FISH are larger than the deletion intervals. Parental FISH testing indicated the deletions in subjects 1–4 and 15 were apparently de novo in origin; additionally, subject 12’s mother did not have the deletion, while her father was unavailable for testing. Three deletions were inherited. Two of these segregated with a developmental phenotype in the family, one from a more severely affected mother and was also present in an affected sister (subject 6) and one from an affected father (subject 16). The third was inherited from an apparently normal father (subject 9) (Tables 2 and and3).3). For the parents of subjects 6 and 9, aCGH confirmed that the deletions were identical in parents and children. Additionally, FISH revealed that the healthy paternal grandmother of subject 9 also carried the deletion. All other parents were unavailable for testing.
Clinical information
Clinical information is presented for subjects 1–9 in Table 2 and for subjects 10–16 in Table 3. Major features for the eight subjects with abnormalities limited to SOX5 include developmental delay/intellectual disability (DD/ID) (9/9), speech delay (8/9), behavior problems (5/9), strabismus (6/9), mild dysmorphic appearance (6/9), brain anomalies (2/5), seizures (2/9), and genital anomalies (2/9) (Table 4). Behavioral aspects include aggressive behavior in subjects 2–4, self-injurious behavior in subject 1, and ADHD in subject 7. Subjects 2 and 4 demonstrated stereotypies but were not formally assessed for autism, while subject 1 received a diagnosis of PDD from his therapists and primary care physician, and subject 3 had a diagnosis of PDD and atypical autism through the TEACCH program (Mesibov and Shea, 2010), which uses assessment batteries including the Childhood Autism Rating Scale (CARS-2) and Psychoeducational Profile – Third Edition (PEP-3). Some minor dysmorphic features were noted in all but subject 2, with the only common feature of frontal bossing seen in 4/9 subjects (Figure 3). Skeletal system involvement was noted as butterfly vertebrae in one and scoliosis in two subjects.
Table 4
Table 4
Summary of features in individuals with 12p12.1 abnormalities in current cohort and in the literature.
Figure 3
Figure 3
Physical features of subjects with SOX5 deletions
Major features for the seven subjects with larger, SOX5-encompassing deletions include: DD/ID (7/7), speech delay (5/5), behavior problems (5/5), dysmorphic features (6/7; Figure 3), clinodactyly/deviated fingers or toes (4/7), skeletal anomalies (4/7), and brain malformations (4/5). No aggressive behavior was noted in this group (Tables 3 and and44).
Case-control comparison
Among 24,081 probands tested with oligonucleotide-based microarrays at Signature Genomics between February 2008 and April 2011, seven deletions within SOX5 were identified; excluding the deletions in subject 8, which may or may not involve a coding exon, due to gaps in probe coverage, and subject 9, which only includes untranslated exons, five of these are known to include coding exons. Additionally, one deletion immediately 5′ of exon 1 was identified in a parental sample (chr12:24,001,784–24,041,797); this healthy parent’s affected child did not carry this deletion. Ten additional larger deletions, involving all or part of SOX5 and additional genes, were identified during this time period. In comparison, in one series of 8,329 control subjects studied on high-resolution Illumina genome-wide SNP arrays (mostly with >550,000 probes) with denser coverage of SOX5 than our arrays (Cooper et al., 2011), 62 deletions were identified in SOX5. Most were intronic, one involved an untranslated exon, and three involved coding exons (Figure 1). Unlike the coding exon deletions in cases, these control deletions may still allow the production of functional long SOX5 isoforms. No whole-gene deletions were detected. Unfortunately, comparison of deletion frequency in cases to controls is complicated by incomplete knowledge of how the deletions affect expression of the various SOX5 isoforms.
SOXD genes—SOX5, SOX6, and SOX13—encode transcription factors that play important roles in the development of many systems and processes such as cell proliferation, differentiation, terminal maturation, and survival. Although no known association of these genes with human disease has been previously noted, it has been hypothesized that such associations will be observed due to the critical role of these genes in a large number of pathways (Lefebvre, 2010). Furthermore, predictive modeling shows SOX5 and SOX6 as being likely haploinsufficient (Huang et al., 2010). A survey of aCGH results among patients referred for clinical testing in our laboratories shows multiple cases with deletions affecting SOX5, including apparently de novo intragenic deletions. Interestingly, almost no cases of deletions or small duplications involving the coding regions of SOX6 or SOX13 have been observed in our patient populations, with only one exception of an intragenic, apparently de novo duplication in SOX6 in a male referred for DD, autism spectrum disorder, and morbid obesity. This difference in the number of copy number variants affecting these genes may be due to critical developmental functions performed by SOX6 and/or SOX13 that cannot be compensated for by SOX5, or it may reflect a greater susceptibility of the SOX5 locus to rearrangement. Our analysis of SOX5 abnormalities suggests that haploinsufficiency of this gene results in speech delays, behavioral problems, and minor dysmorphic features.
Abnormalities involving only SOX5
SOX5 encodes three major transcription products, and the phenotypic consequences of intragenic deletions may depend upon the protein isoforms affected. Subjects 1–4 have de novo deletions that are predicted to result in loss of the primary DNA-binding domain and lead to haploinsufficiency of all three protein isoforms. The de novo translocation in subject 5 would lead to expression of truncated versions of all three protein isoforms that lack the primary DNA-binding domain. The deletions in subject 6 and his affected mother and sister may prevent expression of functional long forms of SOX5 through two mechanisms: either by inducing a translational frameshift by removing exons 4–6 or by losing a putative coiled-coil domain partially encoded by these same exons and presumably critical to homo- and heterodimerization potential. This frameshift would not be predicted if exon 3 is also included in the deletion; however, loss of the coiled-coil domain would still be expected. Deletions in subjects 7 and 8 may eliminate proximal regulatory elements of NM_006940.4, thereby preventing effective transcription initiation. Potential effects, if any, of this deletion on the expression of the other isoforms cannot be predicted without further characterization of the regulation of SOX5 transcription (Figure 1, Table 1). Subjects 1–8 all demonstrate DD, with greatest delay in speech. Additionally, subjects 1–4 and 8 also demonstrate behavior problems, including a diagnosis of PDD in subjects 1 and 3; behavior problems were not noted in subjects 5 or 6. This may be due to variable expressivity, as subjects 5 and 6 are predicted to have altered expression of different isoforms (Table 1).
To help interpret the clinical significance of CNVs in our patient population, comparisons need to be made to rearrangements in the gene observed in a control population (Cooper et al., 2011; Girirajan and Eichler, 2010; Sharp, 2009). A deletion similar to those observed in subjects 7 and 8 was detected in one control sample (Figure 1) and in a healthy parent in our clinical aCGH testing population. The deletion in the control sample retained approximately 3 kb of sequence upstream of exon 1, whereas the deletion in subject 7 removed this 3-kb region as well as the first exon, and, due to gaps between probes, it is unknown if this region is deleted in subject 8 and the parent. The presence of the sequence upstream of exon 1 may allow for normal gene expression to continue, although SOX5 expression levels were not assayed in these subjects. Interestingly, a deletion affecting both exon 9 of NM_006940.4 and the TSS of the short form was observed in one control individual, and two additional control individuals had deletion of the TSS of the short form. While deletion of exon 9 would not be predicted to cause a frameshift in the larger protein products, deletion of the TSS of the short form would be expected to cause reduced expression of this transcript. This may suggest that haploinsufficiency for the short form alone is not generally detrimental to normal phenotypic development. Because the short and long proteins each have distinct tissue-specific expression patterns and contain different functional domains (Kiselak et al., 2010), it is unlikely that short and long forms can completely compensate for each other’s functions, and it remains possible that adding haploinsufficiency of the short form to haploinsufficiency of the long forms can further impact phenotypic expression.
Unlike the deletions in subjects 1–4 and 6, subject 9’s deletion was inherited from a phenotypically normal father and grandmother. The deletion removes two untranslated exons, and a very similar deletion affecting the fourth untranslated exon was observed in one control individual. Deletions within the 5′ untranslated region may not affect expression of the gene or may only affect one of the long forms, leaving the other long form intact. Subject 9’s phenotype is milder than seen in our other subjects; the child does not have delays in language. Therefore, it is possible that her phenotype may not be caused by the deletion in SOX5, or that it may be attributed to reduced penetrance or variable expression.
Larger deletions containing SOX5
We attempted to determine if the phenotypic observations in subjects 1–9 were also seen in subjects with larger deletions containing SOX5. Subjects 10–14 had whole-gene deletions (Figure 2). Subjects 15–16 had deletions of the 5′ end of the gene that remove a transcription start site and the control region and, therefore, should result in haploinsufficiency of at least one of the long forms (Figure 1, Table 1). It is not known if this would affect expression of all products. All of the subjects older than one year with large deletions including SOX5 have speech delay, consistent with the effects of SOX5 haploinsufficiency observed in subjects 1–8. Additionally, all subjects older than one year demonstrate some type of abnormal behaviors, including subject 15 and the father of subject 16, who was described to be Asperger-like. This is similar to what was observed in subjects 1–5, where behavioral problems were seen in most subjects with haploinsufficiency for the long and short isoforms of SOX5 (4/5).
Additional genes within these large deletions may be contributing to these subjects’ phenotypes. Consistent with this hypothesis, we observed that the subjects with larger deletions that include 30–63 genes tend to show more dysmorphic features and have more musculoskeletal anomalies (Tables 3 and and4).4). In the literature, common features reported among individuals with 12p12 deletions include DD/ID, short stature, microcephaly, brachydactyly, clinodactyly, and dysmorphic features including low-set ears, broad nasal bridge, and microretrognathia (Bahring et al., 1997; Boilly-Dartigalongue et al., 1985; Fryns et al., 1990; Glaser et al., 2003; Lu et al., 2009; Magenis et al., 1981; Magnelli and Therman, 1975; Malpuech et al., 1975; Mayeda et al., 1974; Nagai et al., 1995; Orye and Craen, 1975; Stumm et al., 2007; Tenconi et al., 1975) (Table 4). Behavior problems have only been described in one 13-month-old male with poor psychosocial contact (Orye and Craen, 1975), although a majority of these cases were identified through traditional cytogenetic techniques, and the inclusion of SOX5 in the deleted intervals is uncertain. The brachydactyly observed in these individuals is type E, with shortening of the metacarpals and metatarsals, and, along with the short stature and oligodontia seen in some of these individuals, may be due to the deletion of PTHLH within 12p11.22 (Klopocki et al., 2010). In our series, subjects 14 and 16 are deleted for this gene; subject 14 demonstrates brachydactyly, and subject 16 has short stature. There is also an autosomal-dominant hypertension with brachydactyly syndrome (OMIM 112410) due to an inversion of a minimum ~450-kb segment immediately distal to SOX5 and containing no known protein-coding genes but containing putative microRNA-coding gene(s) that show altered splicing in inversion carriers (Bahring et al., 2008). Expression of SOX5 is not altered in these individuals (Bahring et al., 2004). This suggests a gain-of-function mechanism for this disease, and, consistent with that, the individuals in our cohort with deletions of SOX5 and not PTHLH do not demonstrate brachydactyly. However, in our cohort we do not have information on hypertension, which has been described in an individual with a deletion of 12p11.22 (Bahring et al., 1997).
In summary, deletions within SOX5 result in prominent speech delay and frequently in behavior problems. Larger deletions that include all of SOX5 or that remove the 5′ regulatory region, which may or may not alter expression of all protein isoforms, also show language delay, behavioral problems, and more dysmorphic features. These findings support the role of SOX5 in human neurodevelopment. Complete haploinsufficiency of SOX5, with roles in chondrogenesis, may only occasionally result in skeletal abnormalities, such as the butterfly vertebrae and scoliosis in some of our subjects with deletions. Haploinsufficiency of SOX5 may be compensated for by SOX6 so that the resulting phenotype is milder than may have been hypothesized for the developmentally important SOXD family of genes (Lefebvre, 2010). Further research into how various SOX5 deletions impact the function of the SOX5 protein isoforms and identification of additional individuals with SOX5 abnormalities will be helpful in understanding further how loss of this developmentally important gene contributes to neurodevelopmental disease.
Supplementary Material
Supp Data
Acknowledgments
The authors thank the patients and families who contributed clinical information for this study; Erin Dodge (Signature Genomic Laboratories) for her critical editing and preparation of the manuscript; and Beth Torchia, Carrie Hanscom, and Shahrin Ahsan for their technical assistance. This work is supported in part by NIH grants GM061354 (DGAP; C.C.M), HD065286 (J.F.G.), and F32MH087123 (M.E.T.).
Footnotes
J.A.R., N.J.N., R.A.S., B.C.B., and L.G.S. disclose the following possible conflict of interest: they are employees of Signature Genomic Laboratories, PerkinElmer, Inc.
All other authors have no conflict of interest to report.
  • Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403–10. [PubMed]
  • Aza-Carmona M, Shears DJ, Yuste-Checa P, Barca-Tierno V, Hisado-Oliva A, Belinchon A, Benito-Sanz S, Rodriguez JI, Argente J, Campos-Barros A, Scambler PJ, Heath KE. SHOX interacts with the chondrogenic transcription factors SOX5 and SOX6 to activate the aggrecan enhancer. Hum Mol Genet. 2011;20:1547–59. [PubMed]
  • Bahring S, Kann M, Neuenfeld Y, Gong M, Chitayat D, Toka HR, Toka O, Plessis G, Maass P, Rauch A, Aydin A, Luft FC. Inversion region for hypertension and brachydactyly on chromosome 12p features multiple splicing and noncoding RNA. Hypertension. 2008;51:426–31. [PubMed]
  • Bahring S, Nagai T, Toka HR, Nitz I, Toka O, Aydin A, Muhl A, Wienker TF, Schuster H, Luft FC. Deletion at 12p in a Japanese child with brachydactyly overlaps the assigned locus of brachydactyly with hypertension in a Turkish family. Am J Hum Genet. 1997;60:732–5. [PubMed]
  • Bahring S, Rauch A, Toka O, Schroeder C, Hesse C, Siedler H, Fesus G, Haefeli WE, Busjahn A, Aydin A, Neuenfeld Y, Muhl A, Toka HR, Gollasch M, Jordan J, Luft FC. Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12. Hypertension. 2004;43:471–6. [PubMed]
  • Ballif BC, Theisen A, McDonald-McGinn DM, Zackai EH, Hersh JH, Bejjani BA, Shaffer LG. Identification of a previously unrecognized microdeletion syndrome of 16q11.2q12.2. Clin Genet. 2008;74:469–75. [PubMed]
  • Bernstein EF. Reactive oxygen species activate the human elastin promoter in a transgenic model of cutaneous photoaging. Dermatol Surg. 2002;28:132–5. [PubMed]
  • Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, Kuehn MS, Taylor CM, Neph S, Koch CM, Asthana S, Malhotra A, Adzhubei I, Greenbaum JA, Andrews RM, Flicek P, Boyle PJ, Cao H, Carter NP, Clelland GK, Davis S, Day N, Dhami P, Dillon SC, Dorschner MO, Fiegler H, Giresi PG, Goldy J, Hawrylycz M, Haydock A, Humbert R, James KD, Johnson BE, Johnson EM, Frum TT, Rosenzweig ER, Karnani N, Lee K, Lefebvre GC, Navas PA, Neri F, Parker SC, Sabo PJ, Sandstrom R, Shafer A, Vetrie D, Weaver M, Wilcox S, Yu M, Collins FS, Dekker J, Lieb JD, Tullius TD, Crawford GE, Sunyaev S, Noble WS, Dunham I, Denoeud F, Reymond A, Kapranov P, Rozowsky J, Zheng D, Castelo R, Frankish A, Harrow J, Ghosh S, Sandelin A, Hofacker IL, Baertsch R, Keefe D, Dike S, Cheng J, Hirsch HA, Sekinger EA, Lagarde J, Abril JF, Shahab A, Flamm C, Fried C, Hackermuller J, Hertel J, Lindemeyer M, Missal K, Tanzer A, Washietl S, Korbel J, Emanuelsson O, Pedersen JS, Holroyd N, Taylor R, Swarbreck D, Matthews N, Dickson MC, Thomas DJ, Weirauch MT, Gilbert J, Drenkow J, Bell I, Zhao X, Srinivasan KG, Sung WK, Ooi HS, Chiu KP, Foissac S, Alioto T, Brent M, Pachter L, Tress ML, Valencia A, Choo SW, Choo CY, Ucla C, Manzano C, Wyss C, Cheung E, Clark TG, Brown JB, Ganesh M, Patel S, Tammana H, Chrast J, Henrichsen CN, Kai C, Kawai J, Nagalakshmi U, Wu J, Lian Z, Lian J, Newburger P, Zhang X, Bickel P, Mattick JS, Carninci P, Hayashizaki Y, Weissman S, Hubbard T, Myers RM, Rogers J, Stadler PF, Lowe TM, Wei CL, Ruan Y, Struhl K, Gerstein M, Antonarakis SE, Fu Y, Green ED, Karaoz U, Siepel A, Taylor J, Liefer LA, Wetterstrand KA, Good PJ, Feingold EA, Guyer MS, Cooper GM, Asimenos G, Dewey CN, Hou M, Nikolaev S, Montoya-Burgos JI, Loytynoja A, Whelan S, Pardi F, Massingham T, Huang H, Zhang NR, Holmes I, Mullikin JC, Ureta-Vidal A, Paten B, Seringhaus M, Church D, Rosenbloom K, Kent WJ, Stone EA, Batzoglou S, Goldman N, Hardison RC, Haussler D, Miller W, Sidow A, Trinklein ND, Zhang ZD, Barrera L, Stuart R, King DC, Ameur A, Enroth S, Bieda MC, Kim J, Bhinge AA, Jiang N, Liu J, Yao F, Vega VB, Lee CW, Ng P, Yang A, Moqtaderi Z, Zhu Z, Xu X, Squazzo S, Oberley MJ, Inman D, Singer MA, Richmond TA, Munn KJ, Rada-Iglesias A, Wallerman O, Komorowski J, Fowler JC, Couttet P, Bruce AW, Dovey OM, Ellis PD, Langford CF, Nix DA, Euskirchen G, Hartman S, Urban AE, Kraus P, Van Calcar S, Heintzman N, Kim TH, Wang K, Qu C, Hon G, Luna R, Glass CK, Rosenfeld MG, Aldred SF, Cooper SJ, Halees A, Lin JM, Shulha HP, Xu M, Haidar JN, Yu Y, Iyer VR, Green RD, Wadelius C, Farnham PJ, Ren B, Harte RA, Hinrichs AS, Trumbower H, Clawson H, Hillman-Jackson J, Zweig AS, Smith K, Thakkapallayil A, Barber G, Kuhn RM, Karolchik D, Armengol L, Bird CP, de Bakker PI, Kern AD, Lopez-Bigas N, Martin JD, Stranger BE, Woodroffe A, Davydov E, Dimas A, Eyras E, Hallgrimsdottir IB, Huppert J, Zody MC, Abecasis GR, Estivill X, Bouffard GG, Guan X, Hansen NF, Idol JR, Maduro VV, Maskeri B, McDowell JC, Park M, Thomas PJ, Young AC, Blakesley RW, Muzny DM, Sodergren E, Wheeler DA, Worley KC, Jiang H, Weinstock GM, Gibbs RA, Graves T, Fulton R, Mardis ER, Wilson RK, Clamp M, Cuff J, Gnerre S, Jaffe DB, Chang JL, Lindblad-Toh K, Lander ES, Koriabine M, Nefedov M, Osoegawa K, Yoshinaga Y, Zhu B, de Jong PJ. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816. [PMC free article] [PubMed]
  • Blaise R, Grober J, Rouet P, Tavernier G, Daegelen D, Langin D. Testis expression of hormone-sensitive lipase is conferred by a specific promoter that contains four regions binding testicular nuclear proteins. J Biol Chem. 1999;274:9327–34. [PubMed]
  • Boilly-Dartigalongue B, Riviere D, Junien C, Couturier J, Toudic L, Marie F, Castel Y. A new case of partial monosomy of chromosome 12,del(12)(p11.01 to p12.109) confirming the location of the gene for lactate dehydrogenase B. Ann Genet. 1985;28:55–7. [PubMed]
  • Budde LM, Wu C, Tilman C, Douglas I, Ghosh S. Regulation of IkappaBbeta expression in testis. Mol Biol Cell. 2002;13:4179–94. [PMC free article] [PubMed]
  • Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, Williams C, Stalker H, Hamid R, Hannig V, Abdel-Hamid H, Bader P, McCracken E, Niyazov D, Leppig K, Thiese H, Hummel M, Alexander N, Gorski J, Kussmann J, Shashi V, Johnson K, Rehder C, Ballif BC, Shaffer LG, Eichler EE. A copy number variation morbidity map of developmental delay. Nat Genet. 2011;43:838–46. [PMC free article] [PubMed]
  • Deininger PL, Batzer MA. Alu repeats and human disease. Mol Genet Metab. 1999;67:183–93. [PubMed]
  • Duker AL, Ballif BC, Bawle EV, Person RE, Mahadevan S, Alliman S, Thompson R, Traylor R, Bejjani BA, Shaffer LG, Rosenfeld JA, Lamb AN, Sahoo T. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur J Hum Genet. 2010;18:1196–201. [PMC free article] [PubMed]
  • Dy P, Han Y, Lefebvre V. Generation of mice harboring a Sox5 conditional null allele. Genesis. 2008;46:294–9. [PubMed]
  • Fryns JP, Kleczkowska A, Van den Berghe H. Interstitial deletion of the short arm of chromosome 12. Report of a new patient and review of the literature. Ann Genet. 1990;33:43–5. [PubMed]
  • Girirajan S, Eichler EE. Phenotypic variability and genetic susceptibility to genomic disorders. Hum Mol Genet. 2010;19:R176–87. [PMC free article] [PubMed]
  • Glaser B, Rossier E, Barbi G, Chiaie LD, Blank C, Vogel W, Kehrer-Sawatzki H. Molecular cytogenetic analysis of a constitutional de novo interstitial deletion of chromosome 12p in a boy with developmental delay and congenital anomalies. Am J Med Genet A. 2003;116A:66–70. [PubMed]
  • Han K, Lee J, Meyer TJ, Remedios P, Goodwin L, Batzer MA. L1 recombination-associated deletions generate human genomic variation. Proc Natl Acad Sci U S A. 2008;105:19366–71. [PubMed]
  • Huang N, Lee I, Marcotte EM, Hurles ME. Characterising and predicting haploinsufficiency in the human genome. PLoS Genet. 2010;6:e1001154. [PMC free article] [PubMed]
  • Ikeda T, Zhang J, Chano T, Mabuchi A, Fukuda A, Kawaguchi H, Nakamura K, Ikegawa S. Identification and characterization of the human long form of Sox5 (L-SOX5) gene. Gene. 2002;298:59–68. [PubMed]
  • Kiselak EA, Shen X, Song J, Gude DR, Wang J, Brody SL, Strauss JF, 3rd, Zhang Z. Transcriptional regulation of an axonemal central apparatus gene, sperm-associated antigen 6, by a SRY-related high mobility group transcription factor, S-SOX5. J Biol Chem. 2010;285:30496–505. [PMC free article] [PubMed]
  • Klopocki E, Hennig BP, Dathe K, Koll R, de Ravel T, Baten E, Blom E, Gillerot Y, Weigel JF, Kruger G, Hiort O, Seemann P, Mundlos S. Deletion and point mutations of PTHLH cause brachydactyly type E. Am J Hum Genet. 2010;86:434–9. [PubMed]
  • Kwan KY, Lam MM, Krsnik Z, Kawasawa YI, Lefebvre V, Sestan N. SOX5 postmitotically regulates migration, postmigratory differentiation, and projections of subplate and deep-layer neocortical neurons. Proc Natl Acad Sci U S A. 2008;105:16021–6. [PubMed]
  • Lai T, Jabaudon D, Molyneaux BJ, Azim E, Arlotta P, Menezes JR, Macklis JD. SOX5 controls the sequential generation of distinct corticofugal neuron subtypes. Neuron. 2008;57:232–47. [PubMed]
  • Lefebvre V. The SoxD transcription factors--Sox5, Sox6, and Sox13--are key cell fate modulators. Int J Biochem Cell Biol. 2010;42:429–32. [PMC free article] [PubMed]
  • Lefebvre V, Li P, de Crombrugghe B. A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J. 1998;17:5718–33. [PubMed]
  • Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60. [PMC free article] [PubMed]
  • Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–9. [PMC free article] [PubMed]
  • Lu HY, Cui YX, Shi YC, Xia XY, Liang Q, Yao B, Ge YF, Li XJ, Huang YF. A girl with distinctive features of borderline high blood pressure, short stature, characteristic brachydactyly, and 11.47 Mb deletion in 12p11.21–12p12.2 by oligonucleotide array CGH. Am J Med Genet A. 2009;149A:2321–3. [PubMed]
  • Magenis E, Brown MG, Chamberlin J, Donlon T, Hepburn D, Lamvik N, Lovrien E, Yoshitomi M. Resolution of breakpoints in a complex rearrangement by use of multiple staining techniques: confirmation of suspected 12p12.3 intraband by deletion dosage effect of LDHB. Am J Med Genet. 1981;9:95–103. [PubMed]
  • Magnelli NC, Therman E. Partial 12p deletion: a cause for a mental retardation, multiple congenital abnormality syndrome. J Med Genet. 1975;12:105–8. [PMC free article] [PubMed]
  • Malpuech G, Kaplan JC, Rethore MO, Junien C, Geneix A. Une observation de deletion partielle du bras court du chromosome 12. Lyon Med. 1975;233:275–279.
  • Mayeda K, Weiss L, Lindahl R, Dully M. Localization of the human lactate dehydrogenase B gene on the short arm of chromosome 12. Am J Hum Genet. 1974;26:59–64. [PubMed]
  • Mesibov GB, Shea V. The TEACCH program in the era of evidence-based practice. J Autism Dev Disord. 2010;40:570–9. [PubMed]
  • Nagai T, Nishimura G, Kato R, Hasegawa T, Ohashi H, Fukushima Y. Del(12)(p11.21p12.2) associated with an asphyxiating thoracic dystrophy or chondroectodermal dysplasia-like syndrome. Am J Med Genet. 1995;55:16–8. [PubMed]
  • Ng HH, Ciccone DN, Morshead KB, Oettinger MA, Struhl K. Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: a potential mechanism for position-effect variegation. Proc Natl Acad Sci U S A. 2003;100:1820–5. [PubMed]
  • Orye E, Craen M. Short arm deletion of chromosome 12: report of two new cases. Humangenetik. 1975;28:335–42. [PubMed]
  • Pokholok DK, Harbison CT, Levine S, Cole M, Hannett NM, Lee TI, Bell GW, Walker K, Rolfe PA, Herbolsheimer E, Zeitlinger J, Lewitter F, Gifford DK, Young RA. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell. 2005;122:517–27. [PubMed]
  • Rosenfeld JA, Ballif BC, Lucas A, Spence EJ, Powell C, Aylsworth AS, Torchia BA, Shaffer LG. Small deletions of SATB2 cause some of the clinical features of the 2q33.1 microdeletion syndrome. PLoS One. 2009a;4:e6568. [PMC free article] [PubMed]
  • Rosenfeld JA, Ballif BC, Torchia BS, Sahoo T, Ravnan JB, Schultz R, Lamb A, Bejjani BA, Shaffer LG. Copy number variations associated with autism spectrum disorders contribute to a spectrum of neurodevelopmental disorders. Genet Med. 2010;12:694–702. [PubMed]
  • Rosenfeld JA, Leppig K, Ballif BC, Thiese H, Erdie-Lalena C, Bawle E, Sastry S, Spence JE, Bandholz A, Surti U, Zonana J, Keller K, Meschino W, Bejjani BA, Torchia BS, Shaffer LG. Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations. Genet Med. 2009b;11:797–805. [PubMed]
  • Santos-Rosa H, Schneider R, Bannister AJ, Sherriff J, Bernstein BE, Emre NC, Schreiber SL, Mellor J, Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature. 2002;419:407–11. [PubMed]
  • Schneider R, Bannister AJ, Myers FA, Thorne AW, Crane-Robinson C, Kouzarides T. Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol. 2004;6:73–7. [PubMed]
  • Schubeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, van Leeuwen F, Gottschling DE, O’Neill LP, Turner BM, Delrow J, Bell SP, Groudine M. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 2004;18:1263–71. [PubMed]
  • Shaffer LG, Bejjani BA, Torchia B, Kirkpatrick S, Coppinger J, Ballif BC. The identification of microdeletion syndromes and other chromosome abnormalities: Cytogenetic methods of the past, new technologies for the future. Am J Med Genet C Semin Med Genet. 2007;145C:335–345. [PubMed]
  • Sharp AJ. Emerging themes and new challenges in defining the role of structural variation in human disease. Hum Mutat. 2009;30:135–44. [PubMed]
  • Shaw CJ, Lupski JR. Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum Mol Genet. 2004;13(Spec No 1):R57–64. [PubMed]
  • Smits P, Li P, Mandel J, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B, Lefebvre V. The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. Dev Cell. 2001;1:277–90. [PubMed]
  • Sonnenburg S, Zien A, Ratsch G. ARTS: accurate recognition of transcription starts in human. Bioinformatics. 2006;22:e472–80. [PubMed]
  • Stumm M, Klopocki E, Gasiorek-Wiens A, Knoll U, Wirjadi D, Sarioglu N, Wegner RD, Tonnies H. Molecular cytogenetic characterisation of an interstitial deletion 12p detected by prenatal diagnosis. Prenat Diagn. 2007;27:475–8. [PubMed]
  • Talkowski ME, Ernst C, Heilbut A, Chiang C, Hanscom C, Lindgren A, Kirby A, Liu S, Muddukrishna B, Ohsumi TK, Shen Y, Borowsky M, Daly MJ, Morton CC, Gusella JF. Next-generation sequencing strategies enable routine detection of balanced chromosome rearrangements for clinical diagnostics and genetic research. Am J Hum Genet. 2011a;88:469–81. [PubMed]
  • Talkowski ME, Mullegama SV, Rosenfeld JA, van Bon BW, Shen Y, Repnikova EA, Gastier-Foster J, Thrush DL, Kathiresan S, Ruderfer DM, Chiang C, Hanscom C, Ernst C, Lindgren AM, Morton CC, An Y, Astbury C, Brueton LA, Lichtenbelt KD, Ades LC, Fichera M, Romano C, Innis JW, Williams CA, Bartholomew D, Van Allen MI, Parikh A, Zhang L, Wu BL, Pyatt RE, Schwartz S, Shaffer LG, de Vries BB, Gusella JF, Elsea SH. Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. Am J Hum Genet. 2011b;89:551–63. [PubMed]
  • Tenconi R, Baccichetti C, Anglani F, Pellergrino PA, Kaplan JC, Junien C. Partial deletion of the short arm of chromosome 12(p11; p13). Report of a case. Ann Genet. 1975;18:95–8. [PubMed]
  • Traylor RN, Fan Z, Hudson B, Rosenfeld JA, Shaffer LG, Torchia BS, Ballif BC. Microdeletion of 6q16.1 encompassing EPHA7 in a child with mild neurological abnormalities and dysmorphic features: case report. Mol Cytogenet. 2009;2:17. [PMC free article] [PubMed]
  • Wunderle VM, Critcher R, Ashworth A, Goodfellow PN. Cloning and characterization of SOX5, a new member of the human SOX gene family. Genomics. 1996;36:354–8. [PubMed]
  • Xu W, Zhang S, Qiu W, He G, Liu Y, Sun Y, Ma Y, Dong J, Zhang W. Spermatogenesis-related ring finger gene ZNF230 promoter: identification and functional analysis. Mol Biol Rep. 2009;36:1187–93. [PubMed]